Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
Outlook Therapeutics reported a narrower adjusted net loss of $10.9 million, or $0.09 per share, for the third quarter of fiscal 2026, compared to an adjusted net loss of $15.8 million a year ago. GAAP net loss was $20.3 million, or $0.15 per share. The company is advancing the U.S. commercial launch of LYTENAVA, the only FDA-approved ophthalmic bevacizumab, with rollout planned by the end of calendar 2026.
Key figures
- Revenue
- 9000
- Cash
- 11200000
- Adjusted net loss
- 10900000
- Potential sales 2030
- $500 million
- Offering net proceeds
- 51100000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.